Sp103
CURRENT ROLE OF NONBIOLOGIC TREATMENT OPTIONS IN EOE
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed. This session will examine all treatment options, review the importance of treat to target in EoE and examine if the endpoint of the disease, fibrosis can be reversed now or in the future. LIVE STREAM SESSION
The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed. This session will examine all treatment options, review the importance of treat to target in EoE and examine if the endpoint of the disease, fibrosis can be reversed now or in the future. LIVE STREAM SESSION
Presenter
Northwestern University - The Feinberg School of Medicine
Tracks
Related Products
LONGITUDINAL EFFECTS OF TREATMENT ON ESOPHAGEAL DYSMOTILITY IN EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
BASAL ZONE HYPEPLASIA IS DRIVEN BY SUPERBASAL CELLS THAT RETAIN STEM CELL IDENTITY PROGRAMS IN ADULT EOE
Background: Eosinophilic Esophagitis (EoE) is one of the most predominant causes of chronic esophageal symptoms in children. Pathological changes of the esophageal epithelium in EoE are characterized by basal cell hyperplasia (BCH), infiltration of eosinophils and elevated levels of cytokines (e.g…
<i>THE SEVERITY OF REDUCED ESOPHAGEAL DISTENSIBILITY PARALLELS EOSINOPHILIC DISEASE DURATION</i>
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy…
CASED BASED DISCUSSION
SOCIETY: AGA
